Fertility Drugs Market Size, Share & Industry Analysis, By Drug Class (Ovulation Induction Agents, Gonadotropins, hCG-based Trigger Drugs, GnRH Agonists, and Progesterone/Luteal Phase Support Drugs), By Drug (Clomiphene Citrate, Letrozole, FSH, hCG, Progesterone, Cetrorelix, and Ganirelix), By Treatment (ART/IVF Cycle Support, Non-ART Female Fertility Treatment, and Male Fertility Treatment), By Route of Administration (Injectable, Oral, Vaginal, and Others), By End User (Fertility Clinics, Hospitals, Specialty Clinics, and Homecare Settings), and Regional Forecast, 2026-2034

Last Updated: July 18, 2026 | Format: PDF | Report ID: FBI118300

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 6.22% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug Class, Drug, Treatment, Route of Administration, End User, and Region
By Drug Class	Ovulation Induction Agents Gonadotropins hCG-based Trigger Drugs GnRH Agonists GnRH Antagonists Progesterone/Luteal Phase Support Drugs Others
By Drug	Clomiphene Citrate Letrozole FSH hMG hCG Progesterone Cetrorelix Ganirelix Leuprolide Triptorelin Others
By Treatment	ART/IVF Cycle Support Non-ART Female Fertility Treatment Male Fertility Treatment
By Route of Administration	Injectable Oral Vaginal Others
By End User	Fertility Clinics Hospitals Specialty Clinics Homecare/Self-administration Settings Others
By Region	North America (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country) U.S. Canada Europe (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa